antibody

MSD to Buy B-Cell Depletion Therapy from Curon

Major US drugmaker MSD is to pay up to $1.3 billion to acquire CN201, a novel investigational clinical-stage bispecific antibody for the treatment of B-cell associated diseases, from biotechnology company Curon Biopharmaceutical.

CMC Biologics Hikes Capacity in Denmark

Shire Takes Novimmune’s Blood Therapy Rights

Merck Takes Antibody License from Teijin

MRC Licenses Hepatitis C Antibody to China

Mundipharma to Launch Biosimilar Truxima in Europe

Merck Settles Keytruda Patent Disputes

MedImmune and Abpro Spin Out Antibody Firm

Leaving the Patent Cliff Behind